Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carol Khodier is active.

Publication


Featured researches published by Carol Khodier.


Bioorganic & Medicinal Chemistry Letters | 2013

Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction.

Longqin Hu; Sadagopan Magesh; Lin Chen; Lili Wang; Tim Lewis; Yu Chen; Carol Khodier; Daigo Inoyama; Lesa J. Beamer; Thomas J. Emge; Jian Shen; John E. Kerrigan; Ah-Ng Tony Kong; Sivaraman Dandapani; Michelle Palmer; Stuart L. Schreiber; Benito Munoz

A high-throughput screen (HTS) of the MLPCN library using a homogenous fluorescence polarization assay identified a small molecule as a first-in-class direct inhibitor of Keap1-Nrf2 protein-protein interaction. The HTS hit has three chiral centers; a combination of flash and chiral chromatographic separation demonstrated that Keap1-binding activity resides predominantly in one stereoisomer (SRS)-5 designated as ML334 (LH601A), which is at least 100× more potent than the other stereoisomers. The stereochemistry of the four cis isomers was assigned using X-ray crystallography and confirmed using stereospecific synthesis. (SRS)-5 is functionally active in both an ARE gene reporter assay and an Nrf2 nuclear translocation assay. The stereospecific nature of binding between (SRS)-5 and Keap1 as well as the preliminary but tractable structure-activity relationships support its use as a lead for our ongoing optimization.


Cell Metabolism | 2015

High-Throughput Luminescent Reporter of Insulin Secretion for Discovering Regulators of Pancreatic Beta-Cell Function

Sean M. Burns; Amedeo Vetere; Deepika Walpita; Vlado Dančík; Carol Khodier; Jose R. Perez; Paul A. Clemons; Bridget K. Wagner; David Altshuler

Defects in insulin secretion play a central role in the pathogenesis of type 2 diabetes, yet the mechanisms driving beta-cell dysfunction remain poorly understood, and therapies to preserve glucose-dependent insulin release are inadequate. We report a luminescent insulin secretion assay that enables large-scale investigations of beta-cell function, created by inserting Gaussia luciferase into the C-peptide portion of proinsulin. Beta-cell lines expressing this construct cosecrete luciferase and insulin in close correlation, under both standard conditions or when stressed by cytokines, fatty acids, or ER toxins. We adapted the reporter for high-throughput assays and performed a 1,600-compound pilot screen, which identified several classes of drugs inhibiting secretion, as well as glucose-potentiated secretagogues that were confirmed to have activity in primary human islets. Requiring 40-fold less time and expense than the traditional ELISA, this assay may accelerate the identification of pathways governing insulin secretion and compounds that safely augment beta-cell function in diabetes.


Nature Chemical Biology | 2016

Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells

Cecilia Lopez-Sambrooks; Shiteshu Shrimal; Carol Khodier; Daniel P. Flaherty; Natalie Rinis; Jonathan Charest; Ningguo Gao; Peng Zhao; Lance Wells; Tim Lewis; Mark A. Lehrman; Reid Gilmore; Jennifer E. Golden; Joseph N. Contessa

Asparagine (N)-linked glycosylation is a protein modification critical for glycoprotein folding, stability, and cellular localization. To identify small molecules that inhibit new targets in this biosynthetic pathway, we initiated a cell-based high-throughput screen and lead-compound-optimization campaign that delivered a cell-permeable inhibitor, NGI-1. NGI-1 targets oligosaccharyltransferase (OST), a hetero-oligomeric enzyme that exists in multiple isoforms and transfers oligosaccharides to recipient proteins. In non-small-cell lung cancer cells, NGI-1 blocks cell-surface localization and signaling of the epidermal growth factor receptor (EGFR) glycoprotein, but selectively arrests proliferation in only those cell lines that are dependent on EGFR (or fibroblast growth factor, FGFR) for survival. In these cell lines, OST inhibition causes cell-cycle arrest accompanied by induction of p21, autofluorescence, and cell morphology changes, all hallmarks of senescence. These results identify OST inhibition as a potential therapeutic approach for treating receptor-tyrosine-kinase-dependent tumors and provides a chemical probe for reversibly regulating N-linked glycosylation in mammalian cells.


Archive | 2013

The identification and characterization of non-reactive inhibitor of Keap1-Nrf2 interaction through HTS using a fluorescence polarization assay

Lili Wang; Tim Lewis; Yan-Ling Zhang; Carol Khodier; Sadagopan Magesh; Lin Chen; Daigo Inoyama; Yu Chen; Jing Zhen; Longqin Hu; Lesa J. Beamer; Patrick W. Faloon; Sivaraman Dandapani; Jose R. Perez; Benito Munoz; Michelle Palmer; Stuart L Schreiber


Archive | 2014

Identification of ML359 as a Small Molecule Inhibitor of Protein Disulfide Isomerase

Carol Khodier; Lynn VerPlank; Partha Nag; Jun Pu; Jacqueline Wurst; Tatiana Pilyugina; Chris Dockendorff; Christine N. Galinski; Alissa A. Scalise; Freda Passam; Lotte van Hessem; James Dilks; Daniel R. Kennedy; Robert Flaumenhaft; Michelle Palmer; Sivaraman Dandapani; Benito Munoz; Stuart L. Schrieber


Archive | 2014

Table 4, SAR Analysis: Modification of ester functionality

Carol Khodier; Lynn VerPlank; Partha Nag; Jun Pu; Jacqueline Wurst; Tatiana Pilyugina; Chris Dockendorff; Christine N. Galinski; Alissa A. Scalise; Freda Passam; Lotte van Hessem; James Dilks; Daniel R. Kennedy; Robert Flaumenhaft; Michelle Palmer; Sivaraman Dandapani; Benito Munoz; Stuart L. Schrieber


Archive | 2014

Figure 4, Dose-dependent Activity of the Probe (ML359) in the inhibition of PDI-induced insulin aggregation

Carol Khodier; Lynn VerPlank; Partha Nag; Jun Pu; Jacqueline Wurst; Tatiana Pilyugina; Chris Dockendorff; Christine N. Galinski; Alissa A. Scalise; Freda Passam; Lotte van Hessem; James Dilks; Daniel R. Kennedy; Robert Flaumenhaft; Michelle Palmer; Sivaraman Dandapani; Benito Munoz; Stuart L. Schrieber


Archive | 2014

Table 10, Platelet Aggregation Activity and Platelet Aggregation Reversibility: Profile of ML359, CID 70701242 and CID 70701237

Carol Khodier; Lynn VerPlank; Partha Nag; Jun Pu; Jacqueline Wurst; Tatiana Pilyugina; Chris Dockendorff; Christine N. Galinski; Alissa A. Scalise; Freda Passam; Lotte van Hessem; James Dilks; Daniel R. Kennedy; Robert Flaumenhaft; Michelle Palmer; Sivaraman Dandapani; Benito Munoz; Stuart L. Schrieber


Archive | 2014

Table 9, Prior Art Database Search

Carol Khodier; Lynn VerPlank; Partha Nag; Jun Pu; Jacqueline Wurst; Tatiana Pilyugina; Chris Dockendorff; Christine N. Galinski; Alissa A. Scalise; Freda Passam; Lotte van Hessem; James Dilks; Daniel R. Kennedy; Robert Flaumenhaft; Michelle Palmer; Sivaraman Dandapani; Benito Munoz; Stuart L. Schrieber


Archive | 2014

Table 8, Comparison of the Probe ML359 to Project Criteria

Carol Khodier; Lynn VerPlank; Partha Nag; Jun Pu; Jacqueline Wurst; Tatiana Pilyugina; Chris Dockendorff; Christine N. Galinski; Alissa A. Scalise; Freda Passam; Lotte van Hessem; James Dilks; Daniel R. Kennedy; Robert Flaumenhaft; Michelle Palmer; Sivaraman Dandapani; Benito Munoz; Stuart L. Schrieber

Collaboration


Dive into the Carol Khodier's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alissa A. Scalise

Western New England University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christine N. Galinski

Western New England University

View shared research outputs
Top Co-Authors

Avatar

Daniel R. Kennedy

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James Dilks

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge